JP2006510619A5 - - Google Patents

Download PDF

Info

Publication number
JP2006510619A5
JP2006510619A5 JP2004554020A JP2004554020A JP2006510619A5 JP 2006510619 A5 JP2006510619 A5 JP 2006510619A5 JP 2004554020 A JP2004554020 A JP 2004554020A JP 2004554020 A JP2004554020 A JP 2004554020A JP 2006510619 A5 JP2006510619 A5 JP 2006510619A5
Authority
JP
Japan
Prior art keywords
box
hmgb
polypeptide
group
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004554020A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006510619A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/037507 external-priority patent/WO2004046345A2/en
Publication of JP2006510619A publication Critical patent/JP2006510619A/ja
Publication of JP2006510619A5 publication Critical patent/JP2006510619A5/ja
Pending legal-status Critical Current

Links

JP2004554020A 2002-11-20 2003-11-20 抗炎症剤としてのhmgb断片の使用 Pending JP2006510619A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42784102P 2002-11-20 2002-11-20
US42784602P 2002-11-20 2002-11-20
PCT/US2003/037507 WO2004046345A2 (en) 2002-11-20 2003-11-20 Use of hmgb fragments as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
JP2006510619A JP2006510619A (ja) 2006-03-30
JP2006510619A5 true JP2006510619A5 (cg-RX-API-DMAC7.html) 2006-12-28

Family

ID=32329191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004554020A Pending JP2006510619A (ja) 2002-11-20 2003-11-20 抗炎症剤としてのhmgb断片の使用

Country Status (6)

Country Link
EP (1) EP1569684A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006510619A (cg-RX-API-DMAC7.html)
AU (1) AU2003294488B2 (cg-RX-API-DMAC7.html)
CA (1) CA2506328A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ540067A (cg-RX-API-DMAC7.html)
WO (1) WO2004046345A2 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
PT1768677E (pt) * 2004-07-02 2008-10-06 Creabilis Therapeutics Spa Ácidos nucleicos para o tratamento de patologias relacionadas com hmgb1
WO2006012373A2 (en) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
CA2579094C (en) * 2004-09-03 2014-12-02 Creabilis Therapeutics S.P.A. Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-a of hmgb1 to prevent and/or antagonize pathologies induced by hmgb1
JP2008520552A (ja) * 2004-10-22 2008-06-19 メディミューン,インコーポレーテッド Hmgb1に対する高親和性の抗体およびその使用法
WO2006138429A2 (en) * 2005-06-16 2006-12-28 The Feinstein Institute For Medical Research Antibodies against hmgb1 and fragments thereof
WO2007011606A2 (en) * 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
WO2007054090A1 (en) * 2005-11-09 2007-05-18 Pharmexa A/S Therapeutic vaccines targeting hmgb1
JP2010503630A (ja) * 2006-09-15 2010-02-04 クレアビリス・セラピューティクス・エスピーエー HMGB1のBox−AおよびHMGB1のBox−A変異体のポリマー複合体
EP2517723B1 (en) 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Compositions and methods of enhancing immune responses
US8470325B2 (en) 2007-02-15 2013-06-25 Kagoshima University Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody
WO2009133943A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
KR20120135190A (ko) 2009-10-28 2012-12-12 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 골수 간엽계 및/또는 다능성 줄기세포의 혈중 동원(動員)에 의한 조직 재생 촉진제
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
CA2800830C (en) 2010-06-09 2020-09-08 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
EP3358011B1 (en) 2011-04-26 2020-03-04 StemRIM Inc. Peptide for inducing regeneration of tissue and use thereof
JP6253589B2 (ja) 2012-10-25 2017-12-27 株式会社ジェノミックス Hmgb1断片を利用した新規心筋梗塞の治療法
DK2913059T3 (en) * 2012-10-25 2018-06-25 Genomix Co Ltd Hitherto UNKNOWN PROCEDURE FOR TREATMENT OF SPINE INJURY USING HMGB1 FRAGMENT
MX2015009547A (es) 2013-01-28 2015-11-25 Evec Inc Anticuerpo anti-hmgb1 humanizado o fragmento de union al antigeno del mismo.
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
AU2018213671B2 (en) 2017-01-27 2024-06-06 Osaka University Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
EP3595445B1 (en) 2017-03-15 2024-09-04 The Research Institute at Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
AU2018376452A1 (en) 2017-12-01 2020-06-25 Osaka University Ectodermal mesenchymal stem cells and method for producing same
EP3718561A4 (en) 2017-12-01 2021-07-21 Stemrim Inc. Therapy for inflammatory bowel disease
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
JP2022504139A (ja) 2018-10-05 2022-01-13 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムの除去のためのhmgb1タンパク質誘導体
CN111743890A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 水绫霉素或其衍生物的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins

Similar Documents

Publication Publication Date Title
JP2005512507A5 (cg-RX-API-DMAC7.html)
US20200291094A1 (en) Fibronectin type iii domain based scaffold compositions, methods and uses
US6168791B1 (en) Antibodies that bind immunomodulators
EP2396011B1 (en) Fibronectin type iii domain based scaffold compositions, methods and uses
US20080038831A1 (en) IL-23p40 Specific Immunoglobulin Derived Proteins, Compositions, Epitopes, Methods and Uses
US20050129695A1 (en) Anti-amyloid antibodies, compositions, methods and uses
IL90990A (en) Pharmaceuticals and diagnostic preparations containing monoclonal antibodies that react with catechin and a series of cells for their production
EP1578930A2 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
AU2003294488B2 (en) Use of HMGB fragments as anti-inflammatory agents
EP1644416A2 (en) Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2006039470A2 (en) Anti- amyloid antibodies, compositions, methods and uses
JP2003507364A5 (cg-RX-API-DMAC7.html)
RU97101868A (ru) Иммуномодуляторы
BRPI0113420B1 (pt) Anticorpos para il-1beta humano
AU5730198A (en) Treatment of autoimmune disease, including aids
US20050266005A1 (en) Methods and compositions for treating IL-3 related pathologies
JP2012504602A5 (cg-RX-API-DMAC7.html)
SK12082002A3 (sk) Použitie IL-18 inhibítorov a farmaceutický prostriedok s obsahom IL-18 inhibítorov
EP1684703A2 (en) Methods and compositions for treating mcp-1 related pathologies
WO1984004172A1 (en) Monoclonal antibodies to human immune interferon
WO2008076784A2 (en) Methods and compositions for treating il-4 or il-13 related fibrosis related pathologies
US20060246070A1 (en) Methods and compositions for treating renal cell carcinoma related pathologies
EP1699486A2 (en) Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
JP2003523186A5 (cg-RX-API-DMAC7.html)
CN1056245A (zh) 含有bcrf1拮抗物的药物组合物的制备方法